Clinical Development

Aurion Biotech Advances to Phase III Trials with Promising Allogeneic Cell Therapy for Corneal Oedema

4 months ago talkbio0Tagged allogeneic cell therapy, AURN001, Biotechnology, Clinical Development, Cornea, Corneal endothelial dysfunction, Edema, Phase 2 Clinical Trials, Vision

Allogeneic cell therapy, Corneal oedema, Corneal endothelial dysfunction, AURN001, Phase III clinical trials, Vision restoration, Biotechnology, Clinical development

Angitia Biopharmaceuticals Secures $120 Million in Series C Funding to Develop Novel Musculoskeletal Treatments

4 months ago talkbio0Tagged Angitia Biopharmaceuticals, Antibodies, Bispecific, Clinical Development, Musculoskeletal Diseases, Osteogenesis Imperfecta, Osteoporosis, Series, Spinal fusion (procedure)

Angitia Biopharmaceuticals, Series C funding, Musculoskeletal diseases, Osteoporosis, Osteogenesis imperfecta (OI), Spinal fusion, Bispecific antibodies, Clinical development

Lexicon Pharmaceuticals Shifts Focus to Clinical Development Following Zynquista Setbacks

5 months ago talkbio0Tagged (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol, Clinical Development, lexicon, LX9211, LX9851, R&D pipeline, restructuring, United States Food and Drug Administration, Zynquista

Lexicon Pharmaceuticals, Zynquista, FDA, Clinical Development, Restructuring, R&D Pipeline, LX9211, Sotagliflozin, LX9851

Lexicon Pharmaceuticals Shifts Focus to Clinical Development Following FDA Setbacks

5 months ago talkbio0Tagged (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol, Chronic Kidney Diseases, Clinical Development, commercial, lexicon, restructuring, setbacks, Surgical aspects, United States Food and Drug Administration

Lexicon Pharmaceuticals, FDA setbacks, Clinical development focus, Commercial operations elimination, Sotagliflozin, Type 1 diabetes, Chronic kidney disease, Restructuring

Sensei Biotherapeutics Announces Major Restructuring: 46% Workforce Reduction and Closure of Rockville Research Site

5 months ago talkbio0Tagged Clinical Development, Organization administrative structures, Research Site Closure, restructuring, Sensei Biotherapeutics, SNS-101

Sensei Biotherapeutics, workforce reduction, research site closure, organizational restructuring, SNS-101 clinical development

Rapport Therapeutics Faces Regulatory Hurdles in Pain Treatment Trials

6 months ago talkbio0Tagged Clinical Development, RAP-219, Rapport Therapeutics, regulatory, treatment pain

Rapport Therapeutics, pain treatment trials, regulatory challenges, RAP-219, clinical development

Pfizer Terminates Development of Oral RSV Medication Sisunatovir Due to Ongoing Challenges

7 months ago talkbio0Tagged Acquisition (action), Clinical Development, Pfizer, Respiratory syncytial virus, ReViral, RSV, sisunatovir, Termination - Inactive Reason Code

Pfizer, ReViral, RSV, Sisunatovir, Acquisition, Clinical Development, Termination

GSK Advances mRNA Flu Vaccine to Late-Stage Clinical Development Following Positive Phase II Results

7 months ago talkbio0Tagged Clinical Development, Effectiveness, Late stage, RNA, Messenger, Safety, SmithKline Beecham, Vaccines

GSK, mRNA flu vaccine, phase II results, late-stage clinical development, influenza A and B strains, vaccine efficacy, safety profile.

Biogen and Sage Therapeutics Discontinue Development of SAGE-324 for Essential Tremor Following Mid-Stage Trial Failure

9 months ago talkbio0Tagged Biogen, Clinical Development, Essential Tremor, GABA Receptor Modulator, mid-stage trial, nervous system disorder, SAGE-324

Biogen, Sage Therapeutics, SAGE-324, Essential Tremor, Mid-Stage Trial, Neurological Disorder, GABA Receptor Modulator, Clinical Development

Ono Pharmaceutical Strengthens Oncology Portfolio with Acquisition of Deciphera Pharmaceuticals for $2.4 Billion

12 months ago talkbio0Tagged Acquisition (action), cancer treatments, Clinical Development, Collaboration, Deciphera, Dosage Forms, expansion, Generalized, Market, Oncology Pipeline, strategic

Ono Pharmaceutical, Deciphera Pharmaceuticals, oncology pipeline, acquisition, $2.4 billion, cancer treatments, kinase inhibitors, strategic expansion, global market, clinical development, collaboration.